



Tikrit Journal of Pure Science

ISSN: 1813 – 1662 (Print) --- E-ISSN: 2415 – 1726 (Online)

Journal Homepage: <https://tjpsj.org/>



Leishmania mini-exon Gene for Molecular Diagnosis and Genotypic of Cutaneous Leishmaniasis

Evan L. Khlef¹ , Hawri M. Bakr² , Bejan A. Dizayee³ , Hadi M. Alsakee⁴

^{1,2} College of Medicine/Hawler Medical University, Erbil, Iraq.

³ Central Veterinary Laboratory in Kurdistan Region, Erbil, Iraq.

⁴ College of Medicine, Hawler Medical University, International University of Erbil, Erbil, Iraq.

Received: 28 Sep. 2024 Received in revised forum: 3 Dec. 2024 Accepted: 9 Dec. 2024

Final Proof Reading: 3 Aug. 2025 Available online: 25 Aug. 2025

ABSTRACT

Background and objective: In Middle Eastern countries, cutaneous leishmaniasis is still a community health concern. This study aimed to identify the *Leishmania* species in the local area by an accrued method using Polymerase Chain Reaction (PCR) of the mini-exon gene.

Material and methods: Fourteen Gimsa-stained slides were collected for leishmaniasis from the private laboratory. These slides were prepared for patients with clinical manifestations of leishmaniasis. Genomic DNA was extracted using a modified Motazedian protocol. PCR technique was used to amplify all samples using specific primers for the mini-exon gene.

Results: All fourteen samples were positive for leishmaniasis by PCR amplification. Sanger sequencing has been achieved for the positive samples to identify the species. Seven samples out of 14 were identified as *L. infantum*, while the remaining seven samples were identified as *L. major*. The minixon gene DNA data for *Leishmania* species (*L. major* and *L. infantum*) were submitted to the National Center for Biotechnology Information (NCBI). The sequences are given in GenBank accession numbers OP611207 (*L. major*) and OP611208 (*L. infantum*).

Conclusions: Molecular techniques such as PCR and sequencing enhance the accurate diagnosis and management of leishmaniasis.

Keywords: Cutaneous leishmaniasis; Mini-exon gene; PCR.

Name: Evan L. Khlef

E-mail: evan.latef@hmu.edu.krd



©2025 THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY LICENSE
<http://creativecommons.org/licenses/by/4.0/>

الجين المصغر في الليشمانيا للتشخيص الجزيئي والنمط الوراثي في الليشمانيات الجلدية

إيفان لطيف خليف¹، هاوري مصطفى بكر²، بيجان احمد دزيي³، هادي مهدي الساقى⁴

^{1,2} كلية الطب، جامعة هولير الطبية، أربيل، العراق

³ المختبر البيطري المركزي في الإقليم، أربيل، العراق

⁴ كلية الطب، جامعة هولير الطبية، جامعة أربيل الدولية، أربيل، العراق

الملخص

الخلفية والهدف: لا يزال داء الليشمانيات الجلدي (CL) مصدر قلق كبير للصحة العامة في دول الشرق الأوسط. كان الهدف من هذه الدراسة هو تحديد أنواع الليشمانيا باستخدام جين mini-exon. المواد والطرق: تم فحص أربعة عشر شرائح مصبوغة بـ Giemsa من المرضى الذين يعانون من عرض سريري من CL لتحديد أنواع الليشمانيا المسببة. تم استخراج الحمض النووي الجيني باستخدام بروتوكول Motazedian المعدل. تم تضخيم علامة تُعرف باسم جين mini-exon بواسطة تفاعل سلسلة البلمرة (PCR) باستخدام الاشعال المحدد LB-3C و LC-3 L لتأكيد الأنواع. النتائج: أعطى تضخيم PCR نتائج إيجابية لجميع عينات الحمض النووي الـ 14. كشف تسلسل الحمض النووي لجين Mini-exon عن نوعين مختلفين من ليشمانيا، *L. Major* و *L. Infantum*. من بين 14 عينة، تم التعرف على سبعة على أنها *L. infantum* وسبعة تم تحديدها على أنها *L. Major*. تم تقديم تسلسل الحمض النووي لجين mini-exon من أنواع *L. Major* و *L. Infantum* إلى المركز الوطني لمعلومات التكنولوجيا الحيوية (NCBI) وتم إعطاء التسلسلات أرقام انضمام (*L. Major* OP611207 و *L.* OP611208 (*Infantum*) من المركز الوطني لمعلومات التكنولوجيا الحيوية NCBI). الاستنتاجات: تكشف نتائجنا عن مجموعة متنوعة وراثيا من أنواع الليشمانيا التي تسبب CL في هذا المجال.

INTRODUCTION

Leishmaniasis is a worldwide disease that occurs in eighty-nine countries. Its World Health Organization (WHO) spotlighted tropical disease, with more than six hundred people at risk ^(1, 2). Its rate is increasing globally. The reason for increased travel and population migration of infected people into nonendemic regions ⁽³⁻⁶⁾. Leishmaniasis is endemic, particularly in the Mediterranean, Aegean, and Southeast Anatolian regions ⁽⁷⁾. The culture method for diagnosing leishmaniasis is considered a standard method but has low sensitivity. The microscopic method requires skilled staff and has no ability to diagnose species. Molecular techniques are preferred because of their high specificity and sensitivity. The Polymerase

Chain Reaction (PCR) method gives 100% specificity and 92-98% sensitivity. In addition, *Leishmania* spp. could be detected within 24 hours, and the species and subspecies could identified ⁽⁸⁻¹⁰⁾. An entrenched PCR method targeting the mini-exon gene is helpful for directly diagnosing different *Leishmania* species. The mini-exon gene of Kineto plastid protists exists in 100-200 tandemly repeated copies per nuclear genome ^(11, 12). Each repeat consists of three major parts: i) a transcribed 39 bp long mini-exon; ii) a moderately conserved intron; and iii) a non-transcribed highly variable spacer ⁽¹³⁾. Its variant in size allows it to differentiate between the major Old and New World *Leishmania* complexes ⁽¹⁴⁻¹⁶⁾.

In South America, the Mediterranean Basin, and West and Central Asia, leishmania infantum is the causative agent of visceral leishmaniasis. It can also cause cutaneous leishmaniasis, particularly in Middle Eastern countries (17-19).

This study aimed to use PCR of the mini-exon gene to identify the Leishmania species in the local area.

MATERIALS AND METHODS

Sample collection

Fourteen (14) Giemsa-stained slides were collected. The slides prepared for patients show clinical manifestations of cutaneous leishmaniasis. The Patients were referred to a private diagnostic laboratory for further evaluation. The study was conducted between March 2014 and May 2015.

DNA extraction from the samples

DNA was performed from Giemsa-stained slides according to the procedure described by (20), with some modifications; the modification includes neglecting the boiling step, using Qiagen buffers and QIAamp spin column. The smears were scraped off the glass slides. The scraped material was transferred to clean Eppendorf tubes and processed according to Motazedian's protocol. The protocol was modified by neglecting the boiling step and combining it with the QIAamp procedure (QIAGEN, Germany), initially developed to isolate DNA from tissue specimens. Briefly, the scraped material was resuspended in 180 µl of ATL buffer containing 30 µl of proteinase K and incubated at 55°C for one hour. Next, 200 µl of ice-cold ethanol was added. The DNA was prepared using QIAamp spin columns and then well preserved at -80°C until the day of investigation. The concentration and purity of each extracted DNA sample were measured using a Nanodrop spectrophotometer (20). The mean value of the DNA concentration was one (1) at A₂₆₀, and the A₂₆₀/A₂₈₀ ratio was 1.85.

Primer design

DNA sequences of the spliced leader RNA (SL RNA) mini-exon gene of *L. major* OU755536.1 and *L. infantum* LR812935.1 were obtained from NCBI.

The two sequences were used as a control to design the primers. The location of the SL mini-exon sequence was detected, and the primers were designed for the sequence. Figure (1) shows the loci detection for the primers on both control sequences. The reverse primer is designed to hold the restriction enzyme site *Acil*.

Polymerase Chain Reaction

Amplification of the mini-exon gene was accomplished using forward (LB-3C 5'-TTT ATT GGT ATG CGA AAC TTC-3') and reverse (LC-3 L 5'-GCC CGC G(C/T) G TCA CCA CCA-3') primers in a thermal cycler (Master Cycler, Eppendorf, Germany). PCR was performed in a 25 µl mixture of 10 µl reaction buffer, 0.2 mM deoxynucleotide triphosphate, 2.5 mM MgCl₂, 0.4 mM primers, and 0.3 U of Taq polymerase (Qiagen, Australia). Before adding 200 ng of the DNA template, the samples were preheated at 94°C for 10 min. The PCR consisted of 32 cycles of 45 s at 94°C, 45 s at 55°C and 45 s at 72°C. The final extension step was performed at 72°C for 5 min. Ten microliters (10 µL) of PCR products were electrophoresed on a 1% agarose gel containing 4 µL of 10 mg/ml ethidium bromide at 80 volts for 45 min (21-23). After the gel electrophoresis was finished, the result was documented, and the positive DNA band was sliced out of the gel and preserved in a clean Eppendorf tube for the gel purification step; for that reason, ten microliters (10 µL) of the sample were run.

DNA Sequencing and Bioinformatics analyses of the Mini-exon gene

The PCR products of our mini-exon genes were sequenced by GENEWIZ company (NJ, USA). The sequencing methodology involved the Sanger dideoxy sequencing method. The sequencing process used PCR amplicons, which were purified using the Qiagen GEL purification kit, following the manufacturer's instructions provided with the kit. The purified samples were dehydrated by concentrated centrifuge (Eppendorf). The ready-to-send samples were sent to GENEWIZ company (NJ,

USA). The result of the sequencing is sent back to us via email. By using the MUSCLE program, the result was aligned to the control (MHOM/Israel/83/LT252, accession number X69449) sequence of the mini-exon gene to confirm the results and to detect the transcribed 39 bp sequence and the non-transcript sequence of the mini-exon [figure \(2\)](#). Each confirmed mini-exon sequence was aligned to entire NCBI sequences using BLAST (blastn)/National Center for Biotechnology Information (NCBI) to confirm the *Leishmania* species [figure \(3\)](#).

NCBI submission

The confirmed DNA sequences of the mini-exon genes of *Leishmania* species (*L. major* and *L. infantum*) were submitted to the National Center for Biotechnology Information (NCBI). Further confirmation was achieved by assigning accession numbers OP611207 and OP611208 for *L. major* and *L. infantum*, respectively.

Ethics statement

The Hawler Medical University/College of Medicine Ethics Committee approved the Ethical statement of this study.

RESULTS AND DISCUSSION

Fourteen Giemsa-stained slides, each confirmed positive for cutaneous leishmaniasis, were obtained from patients with clinical symptoms revealing the disease. DNA extraction was performed using a modified Motazedian protocol. Amplification of the mini-exon gene was achieved through PCR using specific LB-3C and LC-3 L DNA primers ([Figures \(4\), \(5\) and \(6\)](#)). All the 14 DNA samples yielded positive results. DNA sequencing of the mini-exon gene revealed the presence of two distinct *Leishmania* species, *L. major* and *L. infantum*. Among the 14 samples examined, *L. infantum* was identified in seven (7), while the remaining seven (7) were determined to be *L. major*, as shown in [Table \(1\)](#). The recognized DNA sequences of the mini-exon gene from each *Leishmania* species (*L. major* and *L. infantum*) were submitted to the National Center for Biotechnology Information (NCBI) under accession numbers OP611207 and OP611208 for *L. major* and *L. infantum*, respectively.

Table 1: The number of positive cases of *L. major* and *L. infantum*

Type of sample	Total number of collected samples	Total number of positive samples	<i>L. major</i>	<i>L. infantum</i>
Giemsa-stained slides	14	14	7	7

L. major OU755536.1

```

273061 GCGCCGGGCT GCGGTGGTGA TGGCTTTTAA CTAACGCTAT ATAAGTATCA GTTCTGT AC
273121 TTTATTGGTA TCGGAACTT CCGGAACCTG TCTTCCGGCA AGATTTTGA AGCGCGCAAG
273181 CGCTATTTT TTTTGTGTGC GTGCGTGTGG TGGTGGCGCC CCCCTGCTGT CCGGCGGGTG
273241 GCGCGGCTCC CGCGGCGGTG GCCACGCCGC GCTGCAAGGG TGCGCCCGCG CCGCTGGGGG
273301 CCACGGGGCC GCGGAGCAGG CGTCCCCCGA GCGCCGCGGC CCAGGAGCAA CGCGCCACG
273361 GTGTGCGTGC GCGCGGGCCG CTCCGTCCCG CGGGCGCTGC CGGCGAGTGT GTGTGCGGGG
273421 CGCGGCACCG CCTGGCCCGT GGGGAGCGCG GTGCGCGCG GTGTGCATGA CACGCGCGG
273481 CGTGC GCGG GAACGGCCAC CCCCCAGCG CCGGCTG CCG TGGTGA TGGC TTTTAACTAA
273541 CGCTATATAA GTATCAGTTT CTGTACTTTA TTGGTATGCG AACTTCCGG AACCTGTCTT

```

L. infantum LR812935.1

```

278761 AACTAACGCT ATATAAGTAT CAGTTTCTGT ACTTTATTGG TATGCGAAAC TTC CGGAAGC
278821 TGTCTTCCGG CAACATTTTG GAAGCGCGCA GGCCTCTTT TTTTTTTTGT GTGCGTGTGT
278881 GTGGCGGCGG GCGGGCCGCT GGTCCCGCGC GGTCCGCGGC GGCTTCCGTA GCGGTGGCCC
278941 CGCCGCGCCG AGGGGGCCGC GACGCGCGCG GGCAGGCGTC CCGCAAGCG CCGCGTACT
279001 GGCGCACCGG GCGCGGGGCC TCGTGC GCGCAGCCGTTT CGTCTCCGCG GGGCGCGGCC
279061 CGCCGCGGTG TGTGCCAGG CGCGGCGCCC CGCACC GCCGCGAGGC GAGCCCGGTG
279121 CGCGGCCA TGGTGGTGA CGCGGGGCGCGT GCGCGAGAA CCTCCGCCCC GCGAATGCGG
279181 GCTGTGGGTG TGACGGCTTT CAACTAACGC TATATAAGTA TCAGTTTCTG TACTTTATTG

```

Fig. 1: The primer design for both *L. major* and *L. infantum*.**A****>seq [Organism: Leishmania major] [clone=1e] mini-exon repeat, complete sequence**

```

ACTTTATTGG TATGCGAAAC TTCCGGAAC TCTCTTCCGG CAAGATTTTG
GAAGCGCGCA AGCGCTATTT CATT TTTTGTGTG GTGTGCGTGT GTGTGGCGGC
GGGCCCCCCT GCTGTCCGCG GCGGTGGCCG GCGGCTCCCG TGGCGGTGGC
CACGCCGCAC TACAAGGGTG CGCCGCGGCC GCTGGGGGCC ACGGGGCCGC
GGAGCAGGCG TCCCCGAGG CGCCGCGGCC CAGGAGCAAC GCGGCCGCGG
TGTGCGTGC CGCGGCCGCG TCCGTCTCCG CGGGCGCTGC CGGCCGGAGT
GTGTGTCGGG GCGCGGCGCG CGGCACCGCC TGGCCCGTGG GGAGGCGGTG
CGCGGCAGTG TGCATGACAC GCGGCGGCGT GCGCGGGGAA CGGCCACCCC
CCAGCGCCGG GCTGCGGTGG T

```

B**>seq [Organism: Leishmania infantum] [clone=2e] mini-exon repeat, complete sequence**

```

T TTATTGGTAT GCGAAACTTC CGGAAGCTGT CTTCCG GCAA CATT TTTGAA
GCGCGCAGGC GCTCTTTTT TTTTGTGTG CGTGTGTGTG GCGGCGGGCC
CCCCTGCGGT CCCGCGCGGT CGCCGCGCGC TTCCGTAGCG GTGGCCCCGC
CGCGCCGAGG GGGCCGCGAC GCCGCGGGGC AGGCGTCCCC CAAGGCCCGC
CGTGA CTGGC GCACCGGGCG CGGGGCTGCG GTGCGCGCAG CCGTTTCCGT
CTCCGCGGGG CGCCGCCGCG CGCGGTGTGT GCCAGGCGCG GCGCCCCGCG
ACCGCCCGGC GCGAGGCGAG CCCGGTGCGC GGCCATGGTG GTGACGCGCG
GGCCCGTGC CGGAGAACCT CCGCCCCGCG AATG CCGGCT

```

Fig. 2: Result of the sequencing and detecting the transcribed 39 bp sequence (Green) and the non-transcript sequence (Yellow) of the mini-exon in both Leishmania species (*L. major* (A) and *L. infantum* (B)).




Fig. 3: Alignment to entire NCBI sequences using BLAST (blastn/NCBI) to confirm the *Leishmania* species. (*L. major* (A) and *L. infantum* (B))




Fig. 4: PCR results showed a positive reaction with 400bp. Line 1 is negative control. Lines 2-8 are positive results for *L. major*. Line 7 is a positive result with a partially amplified band, confirmed by sequencing.




Fig. 5: PCR results showed a positive reaction with 391bp. Lines 16, 19, 20, 21, and 22 are positive for *L. infantum*.




Fig. 6: PCR results showed a positive reaction with 391bp. Lines 23, and 24 are positive for *L. infantum*.

The diagnosis of leishmaniasis is based on the signs and symptoms of the disease, and its appearance is not controllable (12, 24). Identifying *Leishmania* species in patients is required to develop good treatment strategies for this parasitic infection (25-27). The molecular-based method is more accurate than culture methods and smears for disease diagnosis. The accuracy of culture methods ranges from 40% to 75%, while that of microscopic examination methods ranges from 74% to 90% (28, 29). In contrast, mini-exon PCR is the most accurate molecular technique for diagnosing leishmaniasis. The accuracy of mini-exon PCR methods ranges from 53.8-98% (30).

Another study reported that one of the most common genetic markers for detecting *Leishmania* species is the mini-exon gene, which has recently been used to identify *Leishmania* species (31, 32). Marfurt et al. concluded that the mini-exon PCR test was more accurate than conventional diagnostic methods and could detect infections in many clinical samples, including paraffin-embedded tissue sections (21). Another study showed that suitable oligonucleotide primers will increase the chance of accurately diagnosing clinical cases (33).

Our study identified two distinct *Leishmania* species, *L. major* and *L. infantum*, as causative agents of Cutaneous leishmaniasis. Other studies have shown that *L. major* and *L. tropica* cause the most cutaneous leishmaniasis (CL) cases in the Mediterranean Basin (34-36).

In this study, *L. infantum* was one of the causative agents of cutaneous leishmaniasis. During our study, we had an opportunity to meet Syrian refugees. Many studies have shown that after the civil war in Syria, the number of cutaneous leishmaniasis patients increased with the settlement of refugees (37-39).

CONCLUSION

As a result, mini-exon amplification is highly accurate and specific compared to other methods for diagnosing and differentiating *Leishmania* spp. However, the mini-exon RFLP technique is required

to discriminate *L. infantum*. *Leishmania infantum* is the causative agent of visceral and cutaneous leishmaniasis in the region.

Acknowledgments: We thank all participants involved in this research.

Funding: None

Authors' contributions: E.L.K. conceived the design, conducted the experiments, and wrote the manuscript. H.M.B., B.A.D, and H.M.A provided the experiment requirements (materials, machine, and lab space).

Availability of data and materials: The data are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate: Approved by the Ethics Committee of the Hawler Medical University/ College of Medicine.

Consent for publication: Not applicable.

Competing interests: The authors declare that they have no competing interests.

REFERENCE

1. Gurjar D, Patra SK, Bodhale N, Lenka N, Saha B. *Leishmania* intercepts IFN- γ R signaling at multiple levels in macrophages. *Cytokine*. 2022;157:155956. <https://doi.org/10.1016/j.cyto.2022.155956>.
2. Kaye PM, Matlashewski G, Mohan S, Le Rutte E, Mondal D, Khamesipour A, et al. Vaccine value profile for leishmaniasis. *vaccine*. 2023;41:S153-S75. <https://doi.org/10.1016/j.vaccine.2023.01.057>.
3. Oryan A, Akbari M. Worldwide risk factors in leishmaniasis. *Asian Pacific journal of tropical medicine*. 2016;9(10):925-32. <https://doi.org/10.1016/j.apjtm.2016.06.021>.
4. Karami M, Gorgani-Firouzjaee T, Chehraz M. Prevalence of cutaneous Leishmaniasis in the Middle East: a systematic review and meta-analysis. *Pathogens and Global Health*. 2023;117(4):356-65.DOI: <https://doi.org/10.1080/20477724.2022.2133452>.
5. Bailey F, Mondragon-Shem K, Hotez P, Ruiz-Postigo JA, Al-Salem W, Acosta-Serrano A, et al. A new perspective on cutaneous leishmaniasis—

Implications for global prevalence and burden of disease estimates. *PLoS neglected tropical diseases*. 2017;11(8):e0005739.

<https://doi.org/10.1371/journal.pntd.0005739>.

6. Noor Waleed Al-Alousy, Fatima Shihab Al-Nasiri. Some of epidemiological criteria associated with cutaneous leishmaniasis in Tikrit city, Salah Al-Din province, Iraq. *Tikrit Journal of Pure Science*. 2024;26(5).DOI: 10.25130/tjps.v26i5.169.

7. Ramezankhani R, Sajjadi N, Nezakati esmaeilzadeh R, Jozi SA, Shirzadi MR. Climate and environmental factors affecting the incidence of cutaneous leishmaniasis in Isfahan, Iran. *Environmental Science and Pollution Research*. 2018;25:11516-26. <https://doi.org/10.1007/s11356-018-1340-8>.

8. Bensoussan E, Nasereddin A, Jonas F, Schnur LF, Jaffe CL. Comparison of PCR assays for diagnosis of cutaneous leishmaniasis. *Journal of clinical microbiology*. 2006;44(4):1435-9.

<https://doi.org/10.1128/jcm.44.4.1435-1439.2006>.

9. Pourmohammadi B, Motazedian M, Hatam G, Kalantari M, Habibi P, Sarkari B. Comparison of three methods for diagnosis of cutaneous leishmaniasis. *Iranian journal of parasitology*. 2010;5(4):1

10. Maysaa Ibrahim Al-Jubori, Abd Alrahman A. Al-Tae, Mohammad A. Al-Faham. Detection of Cutaneous Leishmaniasis species via PCR in Salah Adeen and Baghdad provinces. *Tikrit Journal of Pure Science*. 2024;24(1). DOI: 10.25130/tjps.v24i1.330.

11. Azmi K, Nasereddin A, Ereqat S, Schöni G, Abdeen Z. Identification of Old World *Leishmania* species by PCR–RFLP of the 7 spliced leader RNA gene and reverse dot blot assay. *Tropical Medicine & International Health*. 2010;15(8):872-80. <https://doi.org/10.1111/j.1365-3156.2010.02551.x>.

12. Akhoundi M, Downing T, Votýpka J, Kuhls K, Lukeš J, Cannet A, et al. *Leishmania* infections: Molecular targets and diagnosis. *Molecular aspects of medicine*. 2017;57:1-29.

<https://doi.org/10.1016/j.mam.2016.11.012>.

13. STURM NR, MASLOV DA, GRISARD EC, CAMPBELL DA. Diplonema spp. possess spliced leader RNA genes similar to the Kinetoplastida. *Journal of Eukaryotic Microbiology*. 2001;48(3):325-31.
<https://doi.org/10.1111/j.1550-7408.2001.tb00321.x>.
14. Fernandes O, Murthy VK, Kurath U, Degraeve WM, Campbell DA. Mini-exon gene variation in human pathogenic *Leishmania* species. *Molecular and Biochemical Parasitology*. 1994;66(2):261-71.
[https://doi.org/10.1016/0166-6851\(94\)90153-8](https://doi.org/10.1016/0166-6851(94)90153-8).
15. Ramos A, Maslov DA, Fernandes O, Campbell DA, Simpson L. Detection and Identification of Human Pathogenic *Leishmania* and *Trypanosoma* Species by Hybridization of PCR-Amplified Mini-exon Repeats. *Experimental Parasitology*. 1996;82(3):242-50.
<https://doi.org/10.1006/expr.1996.0031>.
16. Harris E, Kropp G, Belli A, Rodriguez B, Agabian N. Single-step multiplex PCR assay for characterization of New World *Leishmania* complexes. *Journal of clinical microbiology*. 1998;36(7):1989-95.
<https://doi.org/10.1128/jcm.36.7.1989-1995.1998>.
17. Serafim TD, Iniguez E, Oliveira F. *Leishmania infantum*. *Trends in parasitology*. 2020;36(1):80-1. DOI: 10.1016/j.pt.2019.10.006.
18. del Giudice P, Marty P, Lacour JP, Perrin C, Pratlong F, Haas H, et al. Cutaneous leishmaniasis due to *Leishmania infantum*: Case reports and literature review. *Archives of dermatology*. 1998;134(2):193-8. DOI: 10.1001/archderm.134.2.193.
19. Svobodová M, Alten B, Zídková L, Dvořák V, Hlavačková J, Myšková J, et al. Cutaneous leishmaniasis caused by *Leishmania infantum* transmitted by *Phlebotomus tobbi*. *International journal for parasitology*. 2009;39(2):251-6.
<https://doi.org/10.1016/j.ijpara.2008.06.016>.
20. Motazedian H, Karamian M, Noyes H, Ardehali S. DNA extraction and amplification of *Leishmania* from archived, Giemsa-stained slides, for the diagnosis of cutaneous leishmaniasis by PCR. *Annals of Tropical Medicine & Parasitology*. 2002;96(1):31-4.
<https://doi.org/10.1179/000349802125000484>.
21. Marfurt J, Nasereddin A, Niederwieser I, Jaffe CL, Beck H-P, Felger I. Identification and differentiation of *Leishmania* species in clinical samples by PCR amplification of the minixon sequence and subsequent restriction fragment length polymorphism analysis. *Journal of clinical microbiology*. 2003;41(7):3147-53.
<https://doi.org/10.1128/jcm.41.7.3147-3153.2003>.
22. Sambrook J. *Molecular cloning: a laboratory manual*. Cold Spring Harbor Laboratory. 1989
23. Hashm HA, Muhammad Jamal Muhammad, Zuber Ismael Hassan Multiplex PCR Technique for Simultaneous Detection and genotyping of *E. granulosus*, *E. multilocularis*, and other Taeniidae in some intermediate hosts in Erbil Province. *Tikrit Journal of Pure Science*. 2024;29(2):1-6. DOI: 10.25130/tjps.v29i2.1638.
24. Lukeš J, Mauricio IL, Schönián G, Dujardin J-C, Soteriadou K, Dedet J-P, et al. Evolutionary and geographical history of the *Leishmania donovani* complex with a revision of current taxonomy. *Proceedings of the National Academy of Sciences*. 2007;104(22):9375-80.
<https://doi.org/10.1073/pnas.0703678104>.
25. Cantacessi C, Dantas-Torres F, Nolan MJ, Otranto D. The past, present, and future of *Leishmania* genomics and transcriptomics. *Trends in parasitology*. 2015;31(3):100-8. DOI: 10.1016/j.pt.2014.12.012.
26. Akhoundi M, Kuhls K, Cannet A, Votýpka J, Marty P, Delaunay P, et al. A historical overview of the classification, evolution, and dispersion of *Leishmania* parasites and sandflies. *PLoS neglected tropical diseases*. 2016;10(3):e0004349. DOI: <https://doi.org/10.1371/journal.pntd.0004349>.
27. Sundar S, Singh B. Understanding *Leishmania* parasites through proteomics and

implications for the clinic. Expert review of proteomics. 2018;15(5):371-90

<https://doi.org/10.1080/14789450.2018.1468754>.

28. Graça GCd, Volpini AC, Romero GAS, Oliveira Neto MPd, Hueb M, Porrozzi R, et al. Development and validation of PCR-based assays for diagnosis of American cutaneous leishmaniasis and identification of the parasite species. *Memórias do Instituto Oswaldo Cruz*. 2012;107:664-74.

<https://doi.org/10.1590/S0074-02762012000500014>.

29. Tomás-Pérez M, Fisa R, Riera C. The use of fluorescent fragment length analysis (PCR-FFL) in the direct diagnosis and identification of cutaneous *Leishmania* species. *The American Journal of Tropical Medicine and Hygiene*. 2013;88(3):586. DOI: 10.4269/ajtmh.12-0402.

30. Eroglu F, Koltas I, Genc A. Identification of causative species in cutaneous leishmaniasis patients using PCR-RFLP. *J Bacteriol Parasitol*. 2011;2(113):2. <http://dx.doi.org/10.4172/2155-9597.1000113>.

31. Paiva BRd, Secundino NFC, Nascimento JCd, Pimenta PFP, Galati EAB, Junior HA, et al. Detection and identification of *Leishmania* species in field-captured phlebotomine sandflies based on mini-exon gene PCR. *Acta Tropica*. 2006;99(2-3):252-9. <https://doi.org/10.1016/j.actatropica.2006.08.009>.

32. Khorram M, Masjedi H, Tabrizi F, Rezaei M, Tabarsi P, Marjani M, et al. The Accuracy of Diagnosis and Genotyping of *Leishmania* Species Based on Spliced Leader Mini-Exon Gene by Nuclear Magnetic Resonance and Sequencing Assays. *Iranian Journal of Parasitology*. 2023;18(3):331.10.18502/ijpa.v18i3.13756.

33. Oliveira DMd, Lonardoni MVC, Teodoro U, Silveira TGV. Comparison of different primers for PCR-based diagnosis of cutaneous leishmaniasis. *Brazilian Journal of Infectious Diseases*. 2011;15:204-10.

<https://doi.org/10.1590/S1413-86702011000300004>.

34. Serin MS, Daglioglu K, Bagirova M, Allahverdiyev A, Uzun S, Vural Z, et al. Rapid diagnosis and genotyping of *Leishmania* isolates from cutaneous and visceral leishmaniasis by microcapillary cultivation and polymerase chain reaction–restriction fragment length polymorphism of minixon region. *Diagnostic microbiology and infectious disease*. 2005;53(3):209-14.

<https://doi.org/10.1016/j.diagmicrobio.2005.05.007>

35. BenSaid M, Guerbouj S, Saghruni F, Fathallah-Mili A, Guizani I. Occurrence of *Leishmania infantum* cutaneous leishmaniasis in central Tunisia. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2006;100(6):521-6. <https://doi.org/10.1016/j.trstmh.2005.08.012>.

36. Hakkour M, El Alem MM, Hmamouch A, Rhalem A, Delouane B, Habbari K, et al. Leishmaniasis in northern Morocco: predominance of *Leishmania infantum* compared to *Leishmania tropica*. *BioMed Research International*. 2019;2019(1):5327287

37. Özkeklikçi A, Karakuş M, Özbel Y, Töz S. The new situation of cutaneous leishmaniasis after Syrian civil war in Gaziantep city, Southeastern region of Turkey. *Acta Tropica*. 2017;166:35-8. <https://doi.org/10.1016/j.actatropica.2016.10.019>.

38. El Safadi D, Merhabi S, Rafei R, Mallat H, Hamze M, Acosta-Serrano A. Cutaneous leishmaniasis in north Lebanon: re-emergence of an important neglected tropical disease. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2019;113(8):471-6. <https://doi.org/10.1093/trstmh/trz030>.

39. Lindner AK, Richter J, Gertler M, Nikolaus M, Equihua Martinez G, Müller K, et al. Cutaneous leishmaniasis in refugees from Syria: complex cases in Berlin 2015–2020. *Journal of Travel Medicine*. 2020;27(7):taaa161.

<https://doi.org/10.1093/jtm/taaa161>.